×
S&P 500   3,825.39 (-0.16%)
DOW   30,980.97 (+0.04%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.37 (-3.65%)
BABA   117.59 (-2.11%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.21 (+0.19%)
F   11.20 (-0.36%)
DIS   97.79 (+0.63%)
AMC   12.85 (+0.55%)
PFE   52.10 (+0.89%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
S&P 500   3,825.39 (-0.16%)
DOW   30,980.97 (+0.04%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.37 (-3.65%)
BABA   117.59 (-2.11%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.21 (+0.19%)
F   11.20 (-0.36%)
DIS   97.79 (+0.63%)
AMC   12.85 (+0.55%)
PFE   52.10 (+0.89%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
S&P 500   3,825.39 (-0.16%)
DOW   30,980.97 (+0.04%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.37 (-3.65%)
BABA   117.59 (-2.11%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.21 (+0.19%)
F   11.20 (-0.36%)
DIS   97.79 (+0.63%)
AMC   12.85 (+0.55%)
PFE   52.10 (+0.89%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
S&P 500   3,825.39 (-0.16%)
DOW   30,980.97 (+0.04%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.37 (-3.65%)
BABA   117.59 (-2.11%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.21 (+0.19%)
F   11.20 (-0.36%)
DIS   97.79 (+0.63%)
AMC   12.85 (+0.55%)
PFE   52.10 (+0.89%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
NASDAQ:ARGX

argenx Stock Forecast, Price & News

$378.37
-3.74 (-0.98%)
(As of 07/6/2022 09:34 AM ET)
Add
Compare
Today's Range
$373.37
$379.79
50-Day Range
$269.58
$382.11
52-Week Range
$249.50
$383.81
Volume
133 shs
Average Volume
305,477 shs
Market Capitalization
$20.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$368.65

argenx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3.5% Downside
$368.65 Price Target
Short Interest
Bearish
3.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of argenx in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($19.19) to ($17.24) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.57 out of 5 stars

Medical Sector

955th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

159th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

argenx logo

About argenx (NASDAQ:ARGX) Stock

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

ARGX Stock News Headlines

argenx (NASDAQ:ARGX) Trading Down 2.2%
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
650
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/06/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$368.65
High Stock Price Forecast
$460.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
-2.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
19 Analysts

Profitability

Net Income
$-408,270,000.00
Net Margins
-147.47%
Pretax Margin
-74.11%

Debt

Sales & Book Value

Annual Sales
$539.42 million
Book Value
$49.05 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.52 billion
Optionable
Optionable
Beta
0.93














argenx Frequently Asked Questions

Should I buy or sell argenx stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 hold rating, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx
or view top-rated stocks.

What is argenx's stock price forecast for 2022?

19 Wall Street analysts have issued 1 year target prices for argenx's stock. Their ARGX stock forecasts range from $250.00 to $460.00. On average, they anticipate argenx's share price to reach $368.65 in the next twelve months. This suggests that the stock has a possible downside of 2.6%.
View analysts' price targets for argenx
or view top-rated stocks among Wall Street analysts.

How has argenx's stock performed in 2022?

argenx's stock was trading at $350.19 at the beginning of 2022. Since then, ARGX stock has increased by 8.0% and is now trading at $378.37.
View the best growth stocks for 2022 here
.

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for argenx
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) issued its earnings results on Thursday, May, 5th. The company reported ($4.36) EPS for the quarter, topping the consensus estimate of ($5.07) by $0.71. The firm earned $31.48 million during the quarter, compared to the consensus estimate of $12.68 million. argenx had a negative net margin of 147.47% and a negative trailing twelve-month return on equity of 32.54%. During the same period in the prior year, the firm posted ($0.81) EPS.
View argenx's earnings history
.

Who are argenx's key executives?

argenx's management team includes the following people:
  • Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MSc, CEO & Exec. Director (Age 50, Pay $1.28M)
  • Prof. Hans de Haard Ir, Ph.D., Co-Founder & Chief Scientific Officer (Age 62)
  • Mr. Karl Gubitz, Chief Financial Officer (Age 52)
  • Mr. R. Keith Woods, Chief Operating Officer (Age 54)
  • Mr. Arjen Lemmen M.Sc., VP of Corp. Devel. & Strategy (Age 37)
  • Dr. David L. Lacey M.D., Advisor (Age 70, Pay $19.71k)
  • Ms. Andria Wilk, Global Head of Quality (Age 48)
  • Mr. Filip Borgions, VP & Global Head of Technical Operations
  • Ms. Beth DelGiacco, VP and Global Head of Corp. Communications & Investor Relations
  • Ms. Malini Moorthy, Gen. Counsel (Age 52)

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $378.37.

How much money does argenx make?

argenx (NASDAQ:ARGX) has a market capitalization of $20.52 billion and generates $539.42 million in revenue each year. The company earns $-408,270,000.00 in net income (profit) each year or ($11.54) on an earnings per share basis.

How many employees does argenx have?

argenx employs 650 workers across the globe.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for argenx is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.